Nuvalent, Inc. (NUVL)

NASDAQ • Healthcare

$123.96

+$0 (+0.0%)

Market closed

Last close at July 21, 2026 at 20:00 UTC

Open$123.96

Day Range$123.96 - $123.96

Avg. Volume (3M)0

Market Cap$9.1B

52 Week Range

$84.62$123.99

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$450M

EPS (TTM)

-$6.06

ROA (TTM)

-33.81%

Current Ratio

16.14

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-3.5%Q2 2025-$1.18

-3.1%Q3 2025-$1.31

-22.3%Q4 2025-$1.7

+12.8%Q1 2026-$1.29

-3.0%Q2 2026-$1.39

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q2 2026

Miss -3.0%

Nuvalent’s EPS trailed consensus in the preliminary first fiscal quarter of 2026 reported on May 7, with EPS of -$1.39 versus the -$1.35 estimate, -3.0%. Net income was a loss of about $109.3 million, down 29% from a loss of $84.6 million a year ago, and EPS was down 32% from -$1.05 a year ago. Operating income came in at negative about $119.4 million, while operating cash flow was negative about $92.4 million. Next-period consensus calls for EPS of -$1.44 on revenue of $245,455.00.

View full earnings history

About Nuvalent, Inc.

Nuvalent, Inc. develops targeted cancer therapies as a clinical-stage Biotechnology company listed on the NASDAQ as NUVL. The company centers its pipeline on kinase inhibitors for genetically defined tumors, and, in qualitative terms, it remains an early-stage drug developer rather than a commercial oncology company.

Name

Nuvalent, Inc.

CEO

James R. Porter

Website

www.nuvalent.com

Industry

Healthcare

Year Founded

2017

Employees

234

Today's Snapshot

AI-generated

NUVL closed flat at 123.96, while its sector was firmer. At the close, NUVL was within 0% of its 52-week high of 123.99. Nuvalent agreed to be bought by GSK, a drugmaker.

vs S&P 500 Today

Underperforming Market

-0.59%

Updated: October 9, 2026 at 20:13 UTC

Technical Indicators

5 Buy2 Neutral1 Sell

NUVL exhibits a bullish structure with price notably above short-, medium- and long-term moving averages and a strengthening trend signaled by a positive ADX, while MACD is elevated and short-term momentum is slightly positive. Some oscillators are extended—stochastic and MFI read very high and RSI sits near the upper range—but volatility is contained with a small ATR and narrow Bollinger bands, and on-balance volume is constructive. Classic and Fibonacci pivots sit at the current level. Technical takeaway: Strong Buy — trend, moving-average alignment and volume support the bullish backdrop despite overbought indications.

All signals